Acorda Therapeutics Inc (ACORQ)

[surf1944]

7:03AM Acorda Therapeutics announces European Patent Office upholds fampridine (FAMPYRA) patent (ACOR) 29.69 :

Co announced that the European Patent Office Opposition Division has upheld amended claims covering a sustained release formulation of fampridine (FAMPYRA), also known as dalfampridine or 4-aminopyridine, for increasing walking speed in patients with MS through twice daily dosing at 10 mg. The decision of the Opposition Division is open to appeal.
This European patent (EP-1 732 548 B) is set to expire in 2025, absent any additional exclusivity granted based on regulatory review timelines. In addition, FAMPYRA received 10-year market exclusivity upon approval by the European Commission that is set to expire in 2021.